Affiliation:
1. Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
Abstract
Relevance. To introduce the GK-2 compound into clinical practice, it is necessary to conduct a preclinical study of its pharmacokinetics, in particular, the distribution of the studied drug in organs and tissues. The aim is to study the tissue availability of a new original compound GK-2 in rats after its intraperitoneal administration. Methods. Quantitative determination of GK-2 in blood plasma and organ/tissue homogenates of rats was carried out by high-performance liquid chromatography with mass spectrometric detection. Results. The distribution of GK-2 in organs and tissues with varying degrees of vascularization was studied in rats. It was found that after a single intraperitoneal injection of GK-2 at a dose of 150 mg/kg, the studied compound was recorded in blood plasma for 2 hours, its half-life (t1/2el) was 0.4 hours. In organs and tissues, GK-2 was detected from 1.5 to 2 hours. The tissue availability of GK-2 in the liver — blood plasma system was 18.68; "kidneys — blood plasma" — 1.26; "spleen — blood plasma" — 0.68; "skeletal muscles — blood plasma" — 0.31. For the target organ, the brain, the tissue availability was 0.24. In the brain, the time to reach the maximum concentration of GK-2 (0.77 mcg/g) was 0.34 hours. It was found that GK-2 is excreted more slowly from the brain (t1/2el was 0.75 h) than from other organs and tissues (from 0.31 h for the spleen and up to 0.47 h for the kidneys).
Reference18 articles.
1. Piradov M.A. Insul't : poshagovaya instruktsiya / Piradov M.A., Maksimova M.Yu., Tanashyan M.M. – M.: GEOTAR-Media, 2019. 272 s. Piradov MA. Insult : Poshagovaya instrukcya. Piradov MA, Maximova MYu, Tanashyan MM. Moscow: GEOTAR-Media. 2019. (In Russ.).
2. Sims SK, Wilken-Resman B, Smith CJ, et al. Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research. Neural Plast. 2022 Mar 2;2022:3889300. DOI: 10.1155/2022/3889300.
3. Skaper SD. Peptide mimetics of neurotrophins and their receptors. Curr Pharm Des. 2011;17(25):2704–2718. DOI: 10.2174/138161211797415995.
4. Seredenin S.B., Gudasheva T.A. Patent RF. 2011. № 2410392. Dipeptidnye mimetiki neirotrofinov ngf i bdnf. Dostupno po: http://allpatents.ru/patent/2410392.html Ssylka aktivna na 15.09.2023 Seredenin SB, Gudasheva TA. Patent RF. 2011. № 2410392. Dipeptidnye mimetiki nejrotrofinov ngf i bdnf. (In Russ.). Dostupno po: http://allpatents.ru/patent/2410392.html Ssylka aktivna na 15.09.2023.
5. Gudasheva TA, Povarnina PY, Tarasiuk AV, Seredenin SB. Lowmolecular mimetics of nerve growth factor and brain-derived neurotrophic factor: Design and pharmacological properties. Med Res Rev. 2021 Sep;41(5):2746–2774. DOI: 10.1002/med.21721.